Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Cancer: early-phase trial registry
101 of 283 indexed Pancreatic Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 101 currently recruiting · #33 of 28,707 conditions by registered trial count
Pancreatic Cancer: 283 US clinical trials tracked, 101 recruiting.
Pancreatic Cancer is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 101 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 180 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition pancreatic-cancer
OPEN 101 | RECR 36% | LATE 12 | EARLY 180 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
Pancreatic Cancer lists 101 open slots (36% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Cancer recruits in line with its size-band peers.
101 of 283 indexed trials (35.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 19 of 283 trials (6.7%). 165 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreatic Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 279 trials that report a genuine target (sentinel values excluded). 170 of those (60.9%) plan for fewer than 100 participants.
-
Pancreatic Cancer research is mostly interventional.
237 interventional and 46 observational studies make up this index (83.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 6 of 6
Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer
Epeius Biotechnologies
NCT00504998
Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study
Indiana University
NCT00578279
Molecularly Tailored Therapy for Pancreas Cancer
Georgetown University
NCT01888978
Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
Mayo Clinic
NCT02132325
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
NCT04409002
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Novartis Pharmaceuticals
NCT01487785
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Poniard Pharmaceuticals
NCT00465725
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Pfizer
NCT04803305
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
H. Lee Moffitt Cancer Center and Research Institute
NCT01450046
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
BioVex Limited
NCT00402025
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT00703638
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
NCT01161186
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
NCT01420874
Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
Milton S. Hershey Medical Center
NCT00565487
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Andrew Ko
NCT01383538
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Albert Einstein College of Medicine
NCT03403049
A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer
Georgetown University
NCT01051284
Study of CellCept for Advanced Pancreatic Cancer
Columbia University
NCT00997958
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
University of Michigan Rogel Cancer Center
NCT01663272
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03153410
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
National Cancer Institute (NCI)
NCT03801915
Genetic Evaluation of Families With Endocrine Cancers
Jersey Shore University Medical Center
NCT01794676
Changes in Muscle Tissue in Patients With Pancreatic Cancer
Case Comprehensive Cancer Center
NCT00369460
Proton Radiation for Resectable Carcinoma of the Pancreas
University of Florida
NCT00763516
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer
University of Minnesota
NCT01492907
Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer
Boston Scientific Corporation
NCT03998566
Study of a New Technique for Imaging Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT04883775
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
Memorial Sloan Kettering Cancer Center
NCT00003923
A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
Agensys
NCT01608711
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Memorial Sloan Kettering Cancer Center
NCT02241187
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
SWOG Cancer Research Network
NCT00016965
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
OSI Pharmaceuticals
NCT00033241
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Vion Pharmaceuticals
NCT00064051
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 114 |
| Phase 2 | 66 |
| Phase 3 | 10 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Cancer page
283 registered trials, 101 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 101 Pancreatic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Pancreatic Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Cancer condition card totals 283 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.